Differences

This shows you the differences between two versions of the page.

--- endocrine:glp1:semaglutide [2026/02/13 00:16] – [Semaglutide vs Other GLP-1 Agents] andrew2393cns
+++ endocrine:glp1:semaglutide [2026/02/13 00:17] (current) – [Clinical Pearls] andrew2393cns
@@ Line 153: / Line 153: @@
 Semaglutide:
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Weight loss dominant
+  * • Weight loss dominant
 [[endocrine:sglt2:start|SGLT2 Inhibitors]]:
-• Strong heart failure benefit
+  * • Strong heart failure benefit
-• Strong renal protection
+  * • Strong renal protection
 These classes are often combined in cardiometabolic patients.
@@ Line 167: / Line 167: @@
 ===== Clinical Pearls =====
-✔ Weekly or oral option
+  * ✔ Weekly or oral option
-✔ Powerful weight loss
+  * ✔ Powerful weight loss
-✔ Reduces ASCVD events
+  * ✔ Reduces ASCVD events
-✔ Low hypoglycemia risk
+  * ✔ Low hypoglycemia risk
-✔ Not a core heart failure therapy
+  * ✔ Not a core heart failure therapy
-✔ Monitor for GI intolerance
+  * ✔ Monitor for GI intolerance
 --------------------------------------------------------------------